Related to Companion Dx Negotiates License to Epigenomics’ Septin9 Blood Biomarker for CRC Test

• Amarantus Pays Power3 $0.5M for Biomarker IP to Diagnose Parkinson Disease
  
• EMD Millipore, Proteomics International to Validate Diabetic Nephropathy Biomarkers
  
• Scientists Say EGFR Inhibitors Are the Answer to Vemurafenib Resistance in CRC
  
• GSK Taps Epistem for Amplification Platform to Identify Fibrosis Biomarkers
  
• Proteome Sciences to Carry Out Biomarker Analyses for €11M EU-Funded Stroke Hypothermia Trial
  
• Alzheimer’s Association Puts $4.2M into Initiative to Speed Drug, Biomarker Trials
  
• Enterome Raises €5M to Develop Gut Bacteria-Based Disease and Drug-Response Biomarkers
  
• Affymetrix to Distribute Almac’s Expression-Profiling Array for FFPE Samples
  
• Asuragen to Receive $6.8M from the Cancer Prevention and Research Institute of Texas
  
• Ezose, Hirosaki University Sign Glycomics Partnership to Identify Urologic Cancer Biomarkers
  
• Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D
  
• EU Funds Denator, University Collaboration to Develop Cancer Biomarker Platform
  
• OncoMed Taps Genomic Health to Identify Predictive Biomarkers for Anticancer Antibodies
  
• KineMed, CHDI Ally on Biomarkers of Huntington Disease Progression, Drug Efficacy
  
• GSK to Buy Chemoproteomics Firm Cellzome for $99M in Cash
  
• Google Search Engine Forms Basis of Algorithm to Identify Prognostic Cancer Biomarkers
  
• XDx, LabCorp to Develop Lupus Flare Predictor Test
  
• Firefly Bags $500K from Massachusetts Life Science Center for miRNA Biomarker Platform
  
• Erytech, ExonHit Share €8.9M Initial OSEO Funding for Enzyme Depletion Anticancer Project
  
• Affymetrix, MGH Team Up to Develop Biomarker Tests Using QuantiGene ViewRNA Platform